Dexrazoxane

Le dexrazoxane est une molécule chélateur du fer et utilisée comme médicament cardio-protecteur en cas d'utilisation d'anthracyclines.

Efficacité modifier

Il réduit la sévérité et l'incidence des complications cardiaques des anthracyclines données dans le traitement des formes avancées du cancer du sein^[1]. Il fait de même pour celles de la doxorubicine donnée en cas de leucémie aiguë lymphoblastique de l'enfant^[2].

Il existe cependant un doute sur une possible diminution de l'efficacité anticancéreuse lorsque le dexrazoxane est associé à une anthracycline^[3] mais cela n'a pas été retrouvé dans d'autres études^[4]. Il pourrait exister également une augmentation du risque de survenue d'un deuxième cancer chez l'enfant^[5] mais cela reste discuté^[6].

Notes et références modifier

↑ Marty M, Espie M, Llombart A et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy, Ann Oncol, 2006;17:614–622
↑ Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncol, 2010;11:950–961
↑ Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, J Clin Oncol, 1997;15:1318–1332
↑ van Dalen EC, Caron HN, Dickinson HO, Kremer LC, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database Syst Rev, 2008; CD003917
↑ Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease, J Clin Oncol, 2007;25:493–500
↑ Vrooman LM, Neuberg DS, Stevenson KE et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium, Eur J Cancer, 2011;47:1373–1379

[Marty_2006-1] Marty M, Espie M, Llombart A et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy, Ann Oncol, 2006;17:614–622

[Lipshultz_2010-2] Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncol, 2010;11:950–961

[Swain_1997-3] Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, J Clin Oncol, 1997;15:1318–1332

[van_Dalen_2008-4] van Dalen EC, Caron HN, Dickinson HO, Kremer LC, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database Syst Rev, 2008; CD003917

[Tebbi_2007-5] Tebbi CK, London WB, Friedman D et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease, J Clin Oncol, 2007;25:493–500

[Vrooman_2011-6] Vrooman LM, Neuberg DS, Stevenson KE et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium, Eur J Cancer, 2011;47:1373–1379

[1]

[2]

[3]

[4]

[5]

[6]